High-Impact and Late-Breaking FLOW Results
By Katherine Tuttle, MD, Joel M. Topf, MD, FACP - Last Updated: November 8, 2024The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial was still making news at ASN Kidney Week 2024. Katherine Tuttle, MD, was an author on two late-breaking and one high-impact presentation on FLOW results that are still flowing in. Joel Topf, MD, caught up with Dr. Tuttle onsite in San Diego.
Advertisement
Post Tags:Nephrology Videos
Advertisement
Related Posts
Obinutuzumab reduced proteinuria in patients with FSGS who were treatment-resistant or on immunosuppressive therapy.
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.